- Home
- OVID vs BLRX Comparison
OVID vs BLRX Comparison
Compare OVID & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- BLRX
- Stock Information
- Founded
- OVID 2014
- BLRX 2003
- Country
- OVID United States
- BLRX Israel
- Employees
- OVID N/A
- BLRX N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- OVID Health Care
- BLRX Health Care
- Exchange
- OVID Nasdaq
- BLRX Nasdaq
- Market Cap
- OVID 20.6M
- BLRX 17.0M
- IPO Year
- OVID 2017
- BLRX 2011
- Fundamental
- Price
- OVID $0.97
- BLRX $3.71
- Analyst Decision
- OVID Strong Buy
- BLRX Strong Buy
- Analyst Count
- OVID 4
- BLRX 2
- Target Price
- OVID $3.13
- BLRX $19.00
- AVG Volume (30 Days)
- OVID 1.7M
- BLRX 40.4K
- Earning Date
- OVID 08-13-2025
- BLRX 08-14-2025
- Dividend Yield
- OVID N/A
- BLRX N/A
- EPS Growth
- OVID N/A
- BLRX N/A
- EPS
- OVID N/A
- BLRX N/A
- Revenue
- OVID $6,651,000.00
- BLRX $17,251,000.00
- Revenue This Year
- OVID N/A
- BLRX N/A
- Revenue Next Year
- OVID $5.32
- BLRX N/A
- P/E Ratio
- OVID N/A
- BLRX N/A
- Revenue Growth
- OVID 1070.95
- BLRX 1.19
- 52 Week Low
- OVID $0.24
- BLRX $2.30
- 52 Week High
- OVID $1.47
- BLRX $32.26
- Technical
- Relative Strength Index (RSI)
- OVID 81.75
- BLRX 39.17
- Support Level
- OVID $0.48
- BLRX $3.58
- Resistance Level
- OVID $0.87
- BLRX $4.17
- Average True Range (ATR)
- OVID 0.07
- BLRX 0.27
- MACD
- OVID 0.04
- BLRX -0.01
- Stochastic Oscillator
- OVID 90.83
- BLRX 37.11
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.